#sekbio <br>[a]https%3A%2F%2Fwww.sekbio.com%2Fproducts%2Fcytokeratin-19-fragment-cyfra21-1-tumor-marker%2F[/a] <br> <br>Cytokeratins are epithelial markers whose expression don&#039;t lose during malignant transformation. <br>CYFRA 21–1 is a cytokeratin 19 fragment soluble in serum and can use as a circulating tumour marker. Although expressed in all body tissues, it is significant in the lung, particularly lung cancer tissues. <br>CYFRA 21–1 is a sensitive and specific tumour marker of non-small-cell lung cancer (NSCLC), especially the squamous cell subtype. <br>It also reflects the extent of the disease and has an independent prognostic role along with performance status and disease stage in NSCLC. <br>In addition, detection of serum CYFRA 21 1 allows for identifying high-risk patients that may benefit from adjuvant chemotherapy and enables the early detection of progressive disease in recurrent NSCLC. <br>Additionally, CYFRA 21–1 describe as a valuable marker for oesophagal squamous cell carcinoma and therapy monitoring of bladder cancer. <br> <br>The performance data of the CYFRA21-1 Rapid Quantitative Test Kit (CLIA) <br>Manufacturer SEKBIO <br>Parameter CYFRA21-1 <br>Linearity 0.1-500 ng/ml <br>Detection limit 0.1 ng/ml <br>benchmark product Roche <br>Test principle and procedure CYFRA21-1: Add 10 μl of sample + 30 μl of Ra, incubation for 10 minutes cleaning, 30 μl of Rd incubation for 5 minutes. Wash with 200 μl of washing solution. Finally, add 100 μl of A + 100 μl of B. <br> <br>Six point calibration test results <br>Sample Concentration( ng/ml) <br>RLU Average CV S/N <br>546.75 4,445,546 4,404,255 4,487,587 4,445,796 0.94% 4231.40 <br>93.62 706,516 710,963 736,349 717,943 2.24% 683.32 <br>9.57 69,190 68,756 68,034 68,660 0.85% 65.35 <br>1.03 7,703 7,728 7,799 7,743 0.64% 7.37 <br>0.11 1,703 1,727 1,553 1,661 5.68% 1.58 <br>0.01 1,181 1,003 968 1,051 10.87% 1.00  <br> <br>Precision <br>Sample RLU Concentration Sample RLU Concentration <br> <br> <br> <br> <br> <br>1 6,482 0.76 <br> <br> <br> <br> <br>75 552,944 72.72 <br> 5,679 0.72 564,704 74.21 <br> 6,317 0.80 563,241 74.03 <br> 5,976 0.77 558,522 73.43 <br> 6,211 0.82 570,900 75.00 <br> 5,873 0.81 566,827 74.48 <br> 6,055 0.79 545,138 71.72 <br> 6,028 0.79 573,240 75.30 <br> 5,927 0.82 550,118 72.36 <br> 6,166 0.84 555,993 73.10 <br>AVE 6,71.40 0.79 AVE 560,162.70 73.63 <br>SD 231.61 0.03 SD 9187.21 1.17 <br>CV 3.8% 4.3% CV 1.6% 1.6% <br> <br>Limit of detection <br>Sample RLU Concentration <br> <br> <br> <br> <br>Ag Diluent 1,108 1,164 0.025 0.016 <br> 1,124 1,128 0.019 0.019 <br> 1,024 1,037 0.003 0.001 <br> 1,103 1,103 0.015 0.015 <br> 1,055 1,090 0.013 0.007 <br> 1,118 1,043 0.004 0.018 <br> 1,094 1,183 0.029 0.013 <br> 1,040 1,082 0.011 0.004 <br> 947 918 0 0 <br> 1,054 1,110 0.016 0.006 <br>AVE 1,076.25 0.01 <br>SD 64.60 0.01 <br>AVE+2*SD 0.028 <br> <br>Linear <br>Sample（ng/ml) Dilution ratio Concentration value Average <br>438.24 1.0 448.87 443.83 422.03 438.24 <br>350.61 0.8 337.81 349.19 342.22 343.07 <br>262.98 0.6 243.27 247.31 232.15 240.91 <br>175.35 0.4 148.61 151.02 151.09 150.24 <br>87.72 0.2 72.49 69.26 69.64 70.46 <br>0.09 0.0 0.08 0.10 0.09 0.09  <br>Method Comparison <br>Reagents Stability <br>Reagent Sample(ng/ml) Average Deviation <br>2-8℃ 70.00 2,862,814 <br> 10.00 424,472 <br> 0.10 9,674 <br> Antigen diluent 4,025 <br> random sample 21,808 <br> calf serum 4,816 <br>37℃ 1d 70.00 2,717,873 -5.06% <br> 10.00 415,759 -2.05% <br> 0.10 9,322 -3.64% <br> Antigen diluent 4,062 0.91% <br> random sample 21,842 0.16% <br> calf serum 4,626 -3.96% <br>37℃ 3d 70.00 2,720,985 -4.95% <br> 10.00 434,677 2.40% <br> 0.10 9,822 1.52% <br> Antigen diluent 4,339 7.80% <br> random sample 22,399 2.71% <br> calf serum 4,965 3.09% <br>37℃ 7d 70.00 2,683,682 -6.26% <br> 10.00 408,162 -3.84% <br> 0.10 9,285 -4.02% <br> Antigen diluent 4,224 4.93% <br> random sample 23,879 9.49% <br> calf serum 5,120 6.31% <br> <br>Cytokeratin 19 Fragment (CYFRA21-1) Products <br>Name Application <br>Mouse anti-human CYFRA21-1 mAb For immunodiagnostic: ELISA, LFA, CLIA <br>Humanized anti-human CYFRA21-1 mAb <br> <br>CYFRA21-1 Intro <br>In malignant epithelial cells, the activated protease accelerates the degradation of the cells so that a large number of cytokeratin fragments are released into the blood, and the soluble pieces can specifically bind to the two monoclonal antibodies KS19.1 and BM19.21, so it is called CYFRA21 -1. In malignant lung cancer tissues, CYFRA21-1 is abundant, especially in lung squamous cell carcinoma. The molecular weight of CYFRA21-1 is about 30,000 Da. <br> <br>The serum level of CYFRA21-1 was not related to age, gender, smoking, and pregnancy. Pneumonia, tuberculosis, bronchitis, bronchial asthma, emphysema, and other diseases generally do not cause CYFRA21-1 elevation. Benign liver disease renal failure can cause a slight increase, but rarely more than 10ng/ml. <br> <br>Cytokeratin Tumor Marker <br>Cytokeratin (CK) classifies intermediate filaments that constitute the cytoskeleton. There are many types, among which the cytokeratin 19 (CK19) fragment CYFRA21-1 is the most important in the diagnosis of malignant tumors; the release of CK19 increases when cells become cancerous. , After CK19 is degraded by protease or apoptosis, its fragments are released into the blood. The expression of different keratin fragments has the specificity of tissue distribution, squamous cell carcinoma and adenocarcinoma mainly express CK19, small cell undifferentiated carcinoma mainly express CK18 or only a tiny amount of CK19. CYFRA21-1 is a fragment of cytokeratin 19. It is composed of two monoclonal antibodies to cytokeratin 19, the main component of the cell structure. It is mainly found in the cytoplasm of tumor cells of epithelial origin, such as lung cancer and esophageal cancer. All lung squamous cell carcinomas express CYFRA21-1. When the cells become cancerous, the release of CYFRA21-1 due to the necrolysis of tumor cells increases the blood content, reflecting the prognosis and therapeutic efficacy of the disease. Since the serum product of CK19, CYFRA21-1, is a non-organ-specific tumor marker, comprehensive analysis of clinical data should be combined in clinical application to make a more accurate judgment. <br> <br>As a professional tumor marker factory, SEKBIO has high-quality tumor marker for sale. Welcome to contact us if needed.

[a]https%3A%2F%2Fwww.sekbio.com%2Fproducts%2Fcreatine-kinase-mb-ckmb%2F[/a] <br> <br>#CK #MB #protein <br> <br>Creatine kinase isoenzymes are an enzyme component, among which MB type is mainly present in myocardial cells. It is also a kind of cardiac marker. <br> <br>CK MB protein is of great significance in clinical diagnosis. The serum creatine kinase level increases rapidly in various diseases, including muscular atrophy and myocardial infarction. The determination of creatine kinase activity is more reliable than electrocardiogram in the diagnosis of myocardial infarction. In myocardial infarction, creatine kinase increased within six h of onset, peaked at 24 h, and returned to normal within 3-4 days. <br> <br>The isoenzyme CK-MB of creatine kinase has the highest specificity in diagnosis. Creatine kinase has attracted extensive attention and in-depth research because of its essential physiological function and clinical application value. <br> <br>SEKBIO provides related detection raw materials: Mouse anti-human CKMB mAb and Humanized anti-human CKMB mAb.

[a]https%3A%2F%2Fwww.sekbio.com%2Fproducts%2Fc-reaction-protein-crp-inflammatory-marker%2F[/a] <br> <br>#CRP #marker <br> <br>C-reactive protein (CRP) refers to several proteins (acute proteins) that rise sharply in blood plasma in response to infection or tissue damage. <br> <br>CRP marker can activate complement and strengthen the phagocytosis of phagocytes and play an optimizing role, thus removing pathogenic microorganisms and damaged, necrotic, and apoptotic tissue cells from the body and playing an essential protective role in the natural immune process of the body. <br> <br>C-reactive protein is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells. <br>A CRP test measures the amount of CRP in the blood plasma samples to detect inflammation due to acute conditions or to monitor disease severity in chronic conditions. <br> <br>CRP Intro <br>C-reactive protein (CRP) refers to some proteins (acute proteins) that rise sharply in plasma when the body is infected or tissue damaged. CRP can activate complement and strengthen the phagocytosis of phagocytes to play an opsonizing effect, thereby removing pathogenic microorganisms and damaged, necrotic, and apoptotic tissue cells that invade the body and play an important protective role in the body&#039;s natural immune process.

[a]https%3A%2F%2Fwww.sekbio.com%2Fproducts%2Fca19-9-tumor-marker%2F[/a] <br> <br>#SEKBIO <br> <br>CA19-9 Tumor Marker <br>Cancer antigen 19-9 (CA199 Marker )refers to a tumor marker associated with pancreatic, gallbladder, colon, and stomach cancers and is also known as an associated gastrointestinal antigen.  <br>Cancer antigen 19-9 has high sensitivity and specificity for pancreatic cancer. Detection of ca199 tumor marker is helpful for differential diagnosis, disease monitoring, and diagnosis of pancreatic cancer metastasis. <br> <br>SEKBIO is now offering Mouse anti-human CA19-9 mAb and Humanized anti-human CA19-9 mAb. These antibodies are suitable for use in diagnostics, including ELISA, lateral flow, CLIA, etc. And our products are highly consistent with Roche kits and similar antibodies of CanAg. <br> <br>Tumor Marker CA19-9 Antigen <br>Cancer antigen 199(CA19-9 Tumor Marker ) refers to a tumor marker associated with pancreatic cancer, gallbladder cancer, colon cancer, and gastric cancer, also known as a gastrointestinal tract-associated antigen. tumor marker ca199 has high sensitivity and specificity for pancreatic cancer, and its positive rate is between 85% and 95%, and it decreases with the improvement of the condition after surgery.